SCHEMBL8183045

SCHEMBL8183045

[c]1nocc1-c1ccco1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.43
KDM4E B2RXH2 7/20 0.43
HPGD P15428 5/20 0.43
MAPT P10636 4/20 0.43
HSD17B10 Q99714 4/20 0.43
POLB P06746 3/20 0.43
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
TDP1 Q9NUW8 3/20 0.43
BLM P54132 3/20 0.43
PKM P14618 2/20 0.43
ALOX15 P16050 2/20 0.43
CASP1 P29466 2/20 0.43
PTPN7 P35236 2/20 0.43
RECQL P46063 2/20 0.43
CASP7 P55210 2/20 0.43
L3MBTL1 Q9Y468 2/20 0.43
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
USP2 O75604 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL69346 0.68 ALDH1A1 (0.35) ALDH1A1MEN1KMT2ATDP1ALOX15
SCHEMBL5260742 0.68 PTK2 (0.39) MEN1KMT2APKMLMNAGAA
SCHEMBL450165 0.68 ALDH1A1 (0.43) ALDH1A1KDM4EHPGDMAPTHSD17B10
SCHEMBL8062583 0.68 NOTUM (0.38) ALDH1A1KDM4ENPC1RAB9AGAA
SCHEMBL2565902 0.67 ALDH1A1 (0.42) ALDH1A1KDM4EHPGDMAPTHSD17B10
SCHEMBL978864 0.67 ALDH1A1 (0.42) ALDH1A1KDM4EHPGDMAPTHSD17B10
SCHEMBL1799678 0.67 ALDH1A1 (0.63) ALDH1A1KDM4EHPGDMAPTHSD17B10
SCHEMBL4947004 0.64 KDM4E (0.39) ALDH1A1KDM4EHPGDMAPTHSD17B10
SCHEMBL1190969 0.64 HPGDS (0.33)
SCHEMBL4587267 0.64 ALDH1A1 (0.43) ALDH1A1KDM4EHPGDMAPTHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101679297-B LXR and FXR modulators EXELIXIS INC 2012-01-11 CN claimed
CN-101693695-A Pyrimidine derivatives and methods of treatment related to their use ARENA PHARM INC 2010-04-14 CN claimed
CN-1976905-A Pyrimidine derivatives and methods of treatment related to their use TAISHO PHARMACEUTICAL CO LTD (JP) 2007-06-06 CN claimed
CN-1798736-A Novel quinoline, tetrahydroquinazoline and pyrimidine derivatives and methods of treatment related to their use ARENA PHARM INC (JP) 2006-07-05 CN claimed
CN-1582281-A MCH receptor antagonists TAISHO PHARMACEUTICAL CO LTD (JP) 2005-02-16 CN claimed
US-6080763-A INHIBIT THE RELEASE OF INFLAMMATORY CYTOKINES, E.G., TUMOR NECROSIS FACTOR AND INTERLEUKIN-1; USEFUL TO TREAT CHRONIC INFLAMMATORY DISEASE; AUTOIMMUNE DISEASES, E.G. RHEUMATOID ARTHRITIS, OSTEOPOROSIS; PYRAZOLYLUREAS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2000-06-27 US claimed
US-20150297581-A1 RHO KINASE INHIBITORS ALCON INC. (CH) 2015-10-22 US disclosed
CN-102883718-A Analogues for the treatment or prevention of flavivirus infections VERTEX PHARMA 2013-01-16 CN disclosed
CN-102869657-A Analogues for the treatment or prevention of flavivirus infections VERTEX PHARMA 2013-01-09 CN disclosed
CN-101868458-B Isoxazolo-pyridazine derivatives HOFFMANN LA ROCHE 2012-11-28 CN disclosed
CN-101903342-B Substituted N-phenyl-pyrrolidinylmethylpyrrolidine amides and their therapeutic use as histamine H3 receptor modulators SANOFI AVENTIS 2012-11-21 CN disclosed
CN-1791395-B Immunosuppressant compounds and compositions IRM LLC 2012-09-26 CN disclosed
CN-102625808-A Spirocyclic amide derivatives ASTRAZENECA AB 2012-08-01 CN disclosed
CN-1729185-A Nobel compounds having selective inhibiting effect at GSK3 ASTRAZENECA AB (SE) 2006-02-01 CN disclosed
CN-1726210-A Novel compounds having selective inhibiting effect at GSK3 ASTRAZENECA AB (SE) 2006-01-25 CN disclosed
CN-1691944-A Oxadiazoles as modulators of metabotropic glutamate receptor-5 ASTRAZENECA AB (SE) 2005-11-02 CN disclosed
CN-1642938-A Novel compounds ASTRAZENECA AB (SE) 2005-07-20 CN disclosed
CN-1582281-A MCH receptor antagonists TAISHO PHARMACEUTICAL CO LTD (JP) 2005-02-16 CN disclosed
CN-1333767-A Aromatic heterocyclic compounds as antiinflammatory agent BOEHRINGER INGELHELM PHARMACEU (US) 2002-01-30 CN disclosed
CN-1153779-A 2-(4-pyrazoloxy-pyrimidin-5-yl) acetic acid derivatives SANDOZ LTD (CH) 1997-07-09 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150297581-A1 RHO KINASE INHIBITORS ROCK1, ROCK2, CIT ALDH1A1 4263/4885KDM4E 2089/4885HPGD 630/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.